News Release

Mallinckrodt plc announces €45m Investment in Ireland

-- Specialty biopharmaceutical company to establish state-of-the-art Dublin manufacturing facility --
-- Up to 45 skilled pharmaceutical jobs to be created --

DUBLIN, May 20, 2015 –Mallinckrodt plc, a leading global specialty biopharmaceutical company, today announced a €45million investment to expand its Dublin-based operations. A new state-of-the-art manufacturing facility and office building are to be located at College Business and Technology Park, Blanchardstown, Dublin 15. The development will provide 300 jobs during the two-year construction phase and 45 skilled full-time positions once the construction is completed. An Tánaiste, Joan Burton TD, joined the company at the announcement event, as well as U.S. Ambassador to Ireland Kevin O’Malley.

This significant capital investment brings Mallinckrodt Pharmaceuticals’ investment in Ireland to more than €165million over the past 22 years. The company provides treatment options for patients with a wide variety of health conditions, with a particular focus on autoimmune and rare diseases, analgesia, neonatal critical care respiratory therapies, and central nervous system disorders. Mallinckrodt employs more than 120 people at its existing manufacturing site and offices in Dublin.

Speaking at the announcement, An Tánaiste, Joan Burton TD, said: “I am delighted that Mallinckrodt Pharmaceuticals has chosen to make this major new investment in Dublin. The pharmaceutical industry is a key contributor to Ireland’s economy and to Ireland’s growing international reputation as a medical innovation hub. Today’s announcement represents a significant development, both for the wider Dublin region and for Ireland Inc. Mallinckrodt has had a strong and valued presence in Ireland for over 20 years and these plans for this new site support our drive for job creation.”

Mark Trudeau, Chief Executive Officer and President of Mallinckrodt, added: “We are proud to have had a significant presence in Ireland for over two decades, and today marks an important step for the company. Our Irish workforce has served as a tremendous asset to our global operations to date. We are particularly pleased to be making this sizeable capital investment today, continuing our long-standing operations in Ireland.”

The new state-of-the-art facility will include a two-storey manufacturing building, a three-storey administration building and additional areas for future investment on a c.4.85 hectare site.

Welcoming the investment, Dr. David Keenan, Vice President, Global External Supply & Managing Director, Mallinckrodt Pharmaceuticals, Ireland, said, “This exciting new chapter for Mallinckrodt in Ireland is testament to the productivity and ingenuity of our team. We are pleased to establish this new manufacturing operation on Irish soil and to strengthen Ireland’s pharmaceutical credentials in the process.”

Note to Editors
Today’s announcement took place at The Shelbourne Hotel, Dublin 2.

About Mallinckrodt Pharmaceuticals:
Mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. Areas of focus include therapeutic drugs for autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology and pulmonology; neonatal critical care respiratory therapies; and analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. The company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines and devices; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. To learn more about Mallinckrodt, visit

For further information contact:
Carl Gibney, Hume Brophy
Sarah McDonagh, Hume Brophy
+353 (0) 1 662 4712

James Tate, Henley Group
+44 (1491) 570 971